According to filings with the U.S. Securities and Exchange Commission, Bugworks Research is raising up to $15,779,970.00 in new funding. Sources indicate that as part of senior management President, Anand Anandkumar played a key role in securing the recent investment.

About Bugworks Research
Bugworks Research Inc. is a company headquartered in US with subsidiaries in India and Australia developing a novel class of antibiotics to tackle the problem of Antimicrobial Resistance (AMR). Additionally, we have developed a portfolio of novel anticancer agents, with the lead candidate ready for IND submission. Bugworks is developing a novel class of broad-spectrum antibacterial and anticancer agents to treat patients worldwide with our Go-To Globe strategy.

To learn more about Bugworks Research, visit http://www.bugworksresearch.com/

Contact:
Anand Anandkumar, President
818-230-2227
https://www.linkedin.com/in/anand-anandkumar-031825/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.